EXACT Sciences (NASDAQ:EXAS) and BIOQUAL (OTCMKTS:BIOQ) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, institutional ownership and valuation.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for EXACT Sciences and BIOQUAL, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
EXACT Sciences 0 1 11 0 2.92
BIOQUAL 0 0 0 0 N/A

EXACT Sciences currently has a consensus target price of $99.70, suggesting a potential upside of 3.69%. Given EXACT Sciences’ higher possible upside, analysts clearly believe EXACT Sciences is more favorable than BIOQUAL.

Institutional & Insider Ownership

91.1% of EXACT Sciences shares are held by institutional investors. 3.2% of EXACT Sciences shares are held by insiders. Comparatively, 39.2% of BIOQUAL shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.


BIOQUAL pays an annual dividend of $0.60 per share and has a dividend yield of 1.5%. EXACT Sciences does not pay a dividend.

Volatility and Risk

EXACT Sciences has a beta of 1.85, suggesting that its stock price is 85% more volatile than the S&P 500. Comparatively, BIOQUAL has a beta of 0.08, suggesting that its stock price is 92% less volatile than the S&P 500.


This table compares EXACT Sciences and BIOQUAL’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
EXACT Sciences -38.54% -23.58% -11.55%

Valuation and Earnings

This table compares EXACT Sciences and BIOQUAL’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
EXACT Sciences $454.46 million 26.61 -$175.14 million ($1.36) -70.70
BIOQUAL $35.88 million 0.97 $3.66 million N/A N/A

BIOQUAL has lower revenue, but higher earnings than EXACT Sciences.


BIOQUAL beats EXACT Sciences on 7 of the 13 factors compared between the two stocks.

EXACT Sciences Company Profile

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.

BIOQUAL Company Profile

Bioqual, Inc. provides research, development, pre-clinical, consulting, and testing/assay services to commercial clients and government laboratories in the United States. The company provides research services in the areas of cancer, AIDS, hepatitis, influenza, immunology, transgenic, contraception, breeding and development of genetically defined animals, and neurobiology and behavior, as well as zika, dengue, malaria, respiratory syncytial virus, and other infectious diseases. Its services also include sample processing, virus stock generation, infectious virus quantitation, virus neutralization assays, hemagglutination inhibition assays, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation, and other cell-based assays. In addition, the company provides in-vivo animal model related services. Bioqual, Inc. was founded in 1981 and is headquartered in Rockville, Maryland.

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.